NLS drug-2

Evaxion Biotech to present promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma at the 2023 ASCO annual meeting. “We are excited to report that the EVX-01 Phase 1 trial achieved its primary objectives. EVX-01 was well tolerated and induced a higher objective response rate than previously reported for standard of […]

A vaccine against Lyme disease is now being tested in Sweden. “A new vaccine will probably be on the market within a couple of years,” says Johan Sanmartin Berglund, Professor of applied health technology at Blekinge Institute of Technology. About the study Over 15,000 people are included in the study which is led by Blekinge […]

AnaMar has announced results from its Phase I study, and the completion of Phase II enabling pre-clinical studies for its initial orphan indication in systemic sclerosis (SSc) characterized by lung and skin fibrosis. AM1476, a highly selective small molecule, delivered as an orally administered tablet, was found to be safe and well-tolerated at all relevant […]

AlzeCure Pharma has received positive data from the clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain. The phase II data show that ACD440 was able to demonstrate positive proof-of-mechanism (PoM) results in patients with chronic peripheral neuropathic pain, i.e. the drug candidate has an effect on the intended […]

Spago Nanomedical has announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia. The application to start the study has been sent to the ethics committee and patient enrollment is expected to start in the summer 2023. […]

Valo Therapeutics has announced that the first patient has been treated in its trial of PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus) in three tumor types. PeptiCRAd-1 combines two clinically proven cancer immunotherapy approaches: oncolytic adenoviruses and tumor-specific peptides for the generation of strong systemic cytotoxic T-cell responses against multiple tumor antigens. This is achieved by coating […]